Literature DB >> 34370576

Extensively Drug-Resistant Acinetobacter baumannii Nosocomial Pneumonia Successfully Treated with a Novel Antibiotic Combination.

Noor Zaidan1, J Patrik Hornak2, David Reynoso2.   

Abstract

Extremely drug-resistant (XDR) Acinetobacter baumannii causes challenging nosocomial infections. We report the case of a patient with XDR A. baumannii pneumonia and septic shock successfully treated with cefiderocol and a novel antibiotic obtained via expanded access protocol. With focused research and drug development efforts, the poor outcomes associated with these infections may be mitigated.

Entities:  

Keywords:  Acinetobacter baumanii; Gram-negative bacteria; Gram-negative resistance; antibiotic resistance; antimicrobial agents; beta-lactamases; beta-lactams; durlobactam; nosocomial infections; novel antibiotics; sulbactam-durlobactam

Mesh：

Substances：

Year:  2021        PMID： 34370576      PMCID： PMC8522738          DOI： 10.1128/AAC.00924-21

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  10 in total

Review 1.  Acinetobacter baumannii: evolution of antimicrobial resistance-treatment options.

Authors:  Yohei Doi; Gerald L Murray; Anton Y Peleg
Journal:  Semin Respir Crit Care Med       Date:  2015-02-02       Impact factor: 3.119

2.  In Vitro Activity of Sulbactam-Durlobactam against Acinetobacter baumannii-calcoaceticus Complex Isolates Collected Globally in 2016 and 2017.

Authors:  Sarah M McLeod; Samir H Moussa; Meredith A Hackel; Alita A Miller
Journal:  Antimicrob Agents Chemother       Date:  2020-03-24       Impact factor: 5.191

3.  ETX2514 is a broad-spectrum β-lactamase inhibitor for the treatment of drug-resistant Gram-negative bacteria including Acinetobacter baumannii.

Authors:  Thomas F Durand-Réville; Satenig Guler; Janelle Comita-Prevoir; Brendan Chen; Neil Bifulco; Hoan Huynh; Sushmita Lahiri; Adam B Shapiro; Sarah M McLeod; Nicole M Carter; Samir H Moussa; Camilo Velez-Vega; Nelson B Olivier; Robert McLaughlin; Ning Gao; Jason Thresher; Tiffany Palmer; Beth Andrews; Robert A Giacobbe; Joseph V Newman; David E Ehmann; Boudewijn de Jonge; John O'Donnell; John P Mueller; Rubén A Tommasi; Alita A Miller
Journal:  Nat Microbiol       Date:  2017-06-30       Impact factor: 17.745

4.  Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society.

Authors:  Andre C Kalil; Mark L Metersky; Michael Klompas; John Muscedere; Daniel A Sweeney; Lucy B Palmer; Lena M Napolitano; Naomi P O'Grady; John G Bartlett; Jordi Carratalà; Ali A El Solh; Santiago Ewig; Paul D Fey; Thomas M File; Marcos I Restrepo; Jason A Roberts; Grant W Waterer; Peggy Cruse; Shandra L Knight; Jan L Brozek
Journal:  Clin Infect Dis       Date:  2016-07-14       Impact factor: 9.079

5.  Cefiderocol as Rescue Therapy for Acinetobacter baumannii and Other Carbapenem-resistant Gram-negative Infections in Intensive Care Unit Patients.

Authors:  Marco Falcone; Giusy Tiseo; Manuela Nicastro; Alessandro Leonildi; Alessandra Vecchione; Costanza Casella; Francesco Forfori; Paolo Malacarne; Fabio Guarracino; Simona Barnini; Francesco Menichetti
Journal:  Clin Infect Dis       Date:  2021-06-01       Impact factor: 9.079

6.  Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial.

Authors:  Richard G Wunderink; Yuko Matsunaga; Mari Ariyasu; Philippe Clevenbergh; Roger Echols; Keith S Kaye; Marin Kollef; Anju Menon; Jason M Pogue; Andrew F Shorr; Jean-Francois Timsit; Markus Zeitlinger; Tsutae D Nagata
Journal:  Lancet Infect Dis       Date:  2020-10-12       Impact factor: 25.071

7.  Emergence, molecular mechanisms and global spread of carbapenem-resistant Acinetobacter baumannii.

Authors:  Mohammad Hamidian; Steven J Nigro
Journal:  Microb Genom       Date:  2019-10

Review 8.  Carbapenemases: Transforming Acinetobacter baumannii into a Yet More Dangerous Menace.

Authors:  Maria Soledad Ramirez; Robert A Bonomo; Marcelo E Tolmasky
Journal:  Biomolecules       Date:  2020-05-06

9.  Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial.

Authors:  Matteo Bassetti; Roger Echols; Yuko Matsunaga; Mari Ariyasu; Yohei Doi; Ricard Ferrer; Thomas P Lodise; Thierry Naas; Yoshihito Niki; David L Paterson; Simon Portsmouth; Julian Torre-Cisneros; Kiichiro Toyoizumi; Richard G Wunderink; Tsutae D Nagata
Journal:  Lancet Infect Dis       Date:  2020-10-12       Impact factor: 71.421

10.  Contribution of Acinetobacter-derived cephalosporinase-30 to sulbactam resistance in Acinetobacter baumannii.

Authors:  Shu-Chen Kuo; Yi-Tzu Lee; Tsai-Ling Yang Lauderdale; Wei-Cheng Huang; Ming-Fen Chuang; Chien-Pei Chen; Shey-Chiang Su; Kuan-Rong Lee; Te-Li Chen
Journal:  Front Microbiol       Date:  2015-03-25       Impact factor: 5.640
  10 in total
  4 in total

Review 1.  The Role of Colistin in the Era of New β-Lactam/β-Lactamase Inhibitor Combinations.

Authors:  Abdullah Tarık Aslan; Murat Akova
Journal:  Antibiotics (Basel)       Date:  2022-02-20

2.  Mechanisms Underlying Synergistic Killing of Polymyxin B in Combination with Cannabidiol against Acinetobacter baumannii: A Metabolomic Study.

Authors:  Maytham Hussein; Rafah Allobawi; Irini Levou; Mark A T Blaskovich; Gauri G Rao; Jian Li; Tony Velkov
Journal:  Pharmaceutics       Date:  2022-04-03       Impact factor: 6.525

Review 3.  Cefiderocol for the Treatment of Multidrug-Resistant Gram-Negative Bacteria: A Systematic Review of Currently Available Evidence.

Authors:  Chuanhai Wang; Deqing Yang; Yifan Wang; Wentao Ni
Journal:  Front Pharmacol       Date:  2022-04-12       Impact factor: 5.988

4.  Novel Combination Therapy for Extensively Drug-Resistant Acinetobacter baumannii Necrotizing Pneumonia Complicated by Empyema: A Case Report.

Authors:  Dana J Holger; Ashlan J Kunz Coyne; Jing J Zhao; Avnish Sandhu; Hossein Salimnia; Michael J Rybak
Journal:  Open Forum Infect Dis       Date:  2022-03-05       Impact factor: 3.835
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.